Clinical Trials

Nuvance Health™ serves as a research site for clinical trials that explore promising new ways to detect, diagnose, treat and prevent diseases.

Fighting Disease Through Innovation

Joining a clinical trial at Nuvance Health is a way to help make real progress against disease. As a clinical trial site, we test promising new therapies for diagnosing and treating many diseases.

Highlights of our program include:
  • Access to new treatments: Nuvance Health provides a local site for national and international clinical trials. Eligible patients may have access to promising therapies without traveling far from home.
  • Experience: The clinical research team leads a high volume of studies each year and has more than 40 years of collective experience. Nuvance Health’s clinical research coordinators are certified through the Association of Clinical Research Professionals.
  • Focus on patients: Researchers at Nuvance Health are knowledgeable, careful and thorough. We follow guidelines to protect patients and offer suitable treatment options.
  • High standards: Our internal and external Institutional Review Boards review all clinical trials in depth to keep patients safe and comfortable.

A Range of Clinical Trials

Nuvance Health participates in all phases of clinical trials, from Phase I to Phase IV. We study new screening, prevention, diagnostic and treatment options for:

  • Cancer
  • Cardiology
  • Dermatology
  • Electrophysiology
  • Emergency medicine
  • Endocrinology
  • Gastroenterology
  • General surgery
  • Infectious disease
  • Internal medicine
  • Interventional cardiology
  • Nephrology
  • Oncology
  • Pediatrics
  • Perinatology
  • Psychiatry
  • Pulmonary
  • Rheumatology
  • Wound care

Joining a Clinical Trial at Nuvance Health

The care team talks with you about any clinical trials for which you may be eligible. We explain what to expect from a clinical trial, so you can decide if taking part in one is right for you. 


To inquire if you're eligible for a clinical trial, contact: or call (203) 739-4551.

Clinical Trial Listings

  • Alzheimer's

    Evoke Plus
    A randomized double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus)

    A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

  • Arrhythmia

    Assessment of Primary Prevention Patients Receiving an Implanted Cardiac Defibrillator – Systematic Evaluation of ATP
    Adapt Response
    The purpose of this clinical study is to test the hypothesis that market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).
    Brady MRI
    The purpose of this post approval study is to evaluate the long-term safety of the FDA approved St. Jude Medical Tendril MRI™ lead implanted with a SJM Brady MRI implantable pulse generator (IPG) such as the Accent MRI™, Assurity MRI™, Endurity MRI™ pacemaker, or similar model (SJM Brady MRI System) in subjects with a standard bradycardia pacing indication.
    A multicenter, Randomized, Active-control study to evaluate the safety and tolerability of two blinded doses of Abenacimab compared with open label rivaroxaban in patients with Atrial Fibrillation
    Product Surveillance Registry Platform
    Evaluate the periodic reporting of safety and effectiveness of Medtronic market-relased products for their intended use

  • Cervical Hyperplasia

    Reveal 2
    Randomized Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL

  • Cognitive Impairment

    Long-Term Nicotine Treatment of Mild Cognitive Impairment

  • Coronary Disease

    A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients wiith, or at High Risk for, Cardiovascular Disease Who are Statin Intolerant.

    Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting Stents

    HP-4/TIMI 65/ORION 4
    A double-blind, randomized, placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease.

    Vesalius CV
    A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infactrion or Stroke

  • COVID-19

    A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
    ACTIV 5/Big Effect Trial (BET-A/BET-B)

    A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
  • Crohn's Disease

    A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects with Moderate to Severe Crohn's Disease Who Have Failed Anti-TNF Therapy

  • Eosinophilic Esophagitis

    Efficacy and Safety APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) (FLUTE-2)

  • Giant Cell Arteritis

    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant cell Arteritis

  • Heart Failure


    A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency 

    Paraglide HF

    A multicenter, randomized, double-blind, double-dummy, parallel group, active controlled study to evaluate the effect of sacubitril/valsartan (LCZ696) vs. valsartan on changes in NT-proBNP and outcomes, safety and tolerability in HFpEF patients with acute decompensated heart failure (ADHF) who have ben stabilized during hospitalization and initiated in-hospital or within 30 days post discharge.


    The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for future HF events or mortality.


    A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction >40%.


    Randomized Clinical Evaluation of the AccuCinch Ventricular Restoration System in Patients who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF).


    This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients with heart failure with reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤40%) who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure

  • Lupus

    A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated with or without Benlysta (belimumab)

  • Migraine

    Post-Authorization Safety Study Protocol (PASS)

    A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice. 

    Nerivio TCH-008

    A prospective, randomized, double-blind, sham-controlled multi-center clinical study assessing the safety and efficacy of Nerivio for the preventive treatment of migraine

    AMG 334 Erenumab

    Phase 4 Open Label study to evaluate treatment satisfaction with Erenumab in patients with Migraine

  • Multiple Sclerosis

    An Observational Study of Ocrelizumab-Treated Patients with Multiple Sclerosis to Determine the Incidence and Mortality Rates of Breast Cancer and All Malignancies

  • Myocardial Infarction

    A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction
    North American COVID-19 ST-Segment Elevation Myocardial Infarction (NACMI) Registry
    A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome

  • Parkinson's Disease


    A Double-Blind, Placebo-controlled, Randomized, 18-month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 In Study Participants with Early Parkinson's Disease

  • Pulmonary
    Losartan Effects on Emphysema Progression

    A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States.

  • Stroke

    Anticoagulation in ICH Survivors for Stroke Prevention and Recovery (ASPIRE)

  • Valvular

    Optimize PRO
    Optimize PRO TAVR Post Market Study

    Proact XA
    A prospective, randomized, active (warfarin) controlled, parallel-arm clinical trial to determine if patients with a ON-X aortic valve can be maintained safely and effectively on the factor XA inhibitor apixaban

  • Vascular

    A Study of Patients with Lower Extremity Acute Limb Ischemia to Remove Thrombus with the Indigo® Aspiration System